Business Context and Reporting Period
This Form 8-K was filed by Unum Therapeutics Inc. (noting a discrepancy with the request metadata which listed "Cogent Biosciences, Inc.") on August 5, 2019, reporting events occurring on July 31, 2019. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Cambridge, Massachusetts.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt balances, or liquidity ratios. The report focuses exclusively on a contractual amendment rather than financial performance data.
Material Changes
- Entry into Material Definitive Agreement: On July 31, 2019, the Company entered into a "Fourth Amendment" to its Loan Security Agreement with Pacific Western Bank (originally dated January 19, 2017).
- Amendment Details: The amendment modifies the primary depository requirements with Pacific Western Bank.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard incorporation by reference of the full text of the Fourth Amendment (Exhibit 10.1). No unusual items or contingencies were disclosed in the summary text.
Investor Verification Checklist
- Verify the full terms of the Fourth Amendment to the Loan Security Agreement filed as Exhibit 10.1.
- Confirm the specific changes to primary depository requirements and any associated covenants.
- Review the company's latest 10-Q or 10-K for current debt balances and liquidity status, as this 8-K does not contain those figures.
- Clarify the entity name discrepancy between the request metadata ("Cogent Biosciences") and the filing ("Unum Therapeutics").